Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
Status:
Terminated
Trial end date:
2019-07-11
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450
milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive
disorder (MDD).